Skip to content
Open access

Trends and burden of maternal disorders in China from 1990 to 2023: Analysis of the Global Burden of Disease Study 2023

Aug 2026 · Chinese Medical Journal · Vol 139, pp. 2741 - 2749 · 0 citations · 26 references
Medicine

TL;DR

There has been a substantial decline in prevalence, mortality, and burden of maternal disorders in China during the past three decades, however, additional efforts are needed for decreasing the burden of maternal disorders, especially for maternal hypertensive disorders.

Abstract

Abstract Background: Maternal morbidity and mortality are one of the key indicators of social development and are among the most challenging public health problems. This study aimed to analyze the trends and burden of maternal disorders in China from 1990 to 2023. Methods: The crude and age-standardized prevalence, mortality, and disability-adjusted life years (DALYs) for maternal disorders from 1990 to 2023 were analyzed using data on maternal disorders in China from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023. The changing trends of prevalence, mortality, and DALYs were evaluated by the average annual percentage change (AAPC) calculated using a log-transformed linear regression model. The ranks of the leading causes for maternal disorders in terms of prevalence, mortality, and DALYs in 1990, 2015, and 2023 were estimated to determine the impact of changes in the fertility strategy on maternal disorder patterns as China implemented the two-child policy in 2015. Results: In 2023, the age-standardized prevalence, mortality, and DALYs of maternal disorders among reproductive women aged 15–49 years in China were 193.04 (95% confidence interval [CI]: 192.56–193.54), 0.30 (95% CI: 0.28–0.32), and 27.78 (95% CI: 27.59–27.97) per 100,000 population, respectively. The prevalence showed a declining trend with fluctuations, and the mortality and DALYs both showed consistent decrease from 1990 to 2023, with AAPCs of −1.41% (95% CI: −1.92% to −0.90%), −10.64% (95% CI: −11.18% to −10.11%), and −9.37% (95% CI: −9.87% to −8.88%), respectively. In terms of the leading cause of death among the 10 available maternal disorders in GBD, maternal hemorrhage ranked first in 1990 (3.53 per 100,000) but decreased to third in 2015 (0.10 per 100,000) and 2023 (0.05 per 100,000). Among the 10 available maternal disorders in GBD 2023, the prevalence of maternal hypertensive disorders changed from first in 1990 to second both in 2015 and 2023. The other direct maternal disorders became the leading causes of prevalence and DALY during 2015 to 2023. Indirect maternal deaths ranked as the leading cause of mortality during 2015 to 2023. Conclusions: There has been a substantial decline in prevalence, mortality, and burden of maternal disorders in China during the past three decades. However, additional efforts are needed for decreasing the burden of maternal disorders, especially for maternal hypertensive disorders.

Read PDF

Similar papers

Open access Sep 2026

Assessment of the Burden of Maternal Hypertensive Disorders and the Quality of Care in China: A Systematic Analysis of the Global Burden of Disease (GBD) 2021 Study

Objectives This study aims to analyze the disease burden and quality of care associated with maternal hypertensive disorders in China over time and across age groups from 1990 to 2021. Methods This study employs statistical methods, including joinpoint regression analysis, decomposition analysis, age-period-cohort anal...

Wei-Wei Wang, Xun Jiang, Jia-Yao Long et al. · 0 citations
Sep 2026

Burden, trends, and inequalities of anxiety disorders in the Western Pacific region, 1990-2023: A systematic analysis of the Global Burden of Disease Study 2023.

BACKGROUND Anxiety disorders (ADs) are a leading non-fatal cause of global disease burden, yet a detailed assessment of their burden, trends, and socioeconomic inequalities in the Western Pacific region is lacking. METHODS Using data from the Global Burden of Disease (GBD) Study 2023, we estimated prevalence, inciden...

Zhi-Li Zou, Fu-Gui Jiang, Yu Ye et al. · 0 citations
Open access Aug 2026

Analysis of the global burden of maternal and neonatal diseases and future trends.

Despite global progress, marked inequalities persist, and forecasts indicate continued prevalence rise and substantial mortality reduction by 2031, with persistent inequalities.

Mei Zhao, Chun-Mei Qiu, Li-ping Cai et al. · 0 citations
Open access Sep 2026

Global burdens of diabetes mellitus in adolescents from 1990 to 2023 and future trend predictions: An analysis of the Global Burden of Disease study 2023

The burden of adolescent DM increased considerably from 1990 to 2023, with marked heterogeneity by age, sex, and geography, and ARIMA forecasts indicate that ASIR, ASPR, and ASDR are projected to continue increasing through 2040, while ASMR is expected to remain low and stable.

Xin-Yi Qiu, Li-Mei Guan, Hui Liu · 0 citations
Review Open access Sep 2026

Burden of ischemic stroke in China from 1990 to 2050: A systematic review and analysis of Global Burden of Disease Study 2021

Abstract Background Comprehensive understanding of the ischemic stroke (IS) burden in China is critical for policy and medical resource allocation. We aimed to identify the most up‐to‐date IS burden by age‐ and sex‐specific temporal trends in China and forecast to 2050. Methods Based on the Global Burden of Disease, In...

Yi-Jun Zhang, Jinqiao Zhu, Xue Xia et al. · 0 citations
2026

Burden, trends, and forecasts of ischemic heart disease in the Gulf Cooperation Council Countries, 1990 to 2023: a systematic analysis from the Global Burden of Disease study 2023

Objective: This study aimed to assess the burden, long-term trends, sex-specific inequalities, and future projections of ischemic heart disease (IHD) in Gulf Cooperation Council (GCC) countries, 1990 to 2023. Methods: Data were extracted from the Global Burden of Disease (GBD) 2023 study. Sex- and age-standardized in...

Raghad Alhebshi, Hasnah Hawsawi, Mada Aljedaany et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.